Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Reports 45-Percent Increase in Q3 Revenues

NEW YORK, Nov. 4 (GenomeWeb News) - Cepheid yesterday reported a 45-percent increase in revenue for the third quarter of 2005.

 

Revenues for the quarter ended Sept. 30 totaled $20.4 million, compared to $14.1 million during the same quarter last year. The company attributed the increase primarily to a growth in product sales, including sales of reagents and disposables.

 

R&D spending during the quarter increased slightly to $4.8 million, compared to $4 million during the third quarter last year.

 

Cepheid reported a net loss of $3.3 million during the third quarter, compared with a net loss of $2.9 million during the same quarter last year.

 

As of Sept. 30, Cepheid had $10 million in cash and cash equivalents, and $30.2 million in marketable securities.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.